Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies-Reference-Cited by-同舟云学术

Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies

Published:2021-10 Issue:10 Volume:2 Page:100224
ISSN:2666-3643
Container-title:JTO Clinical and Research Reports
language:en
Short-container-title:JTO Clinical and Research Reports

Author:

Jang Seong Bok,Kim Kyeong Bae,Sim Sujin,Cho Byoung Chul,Ahn Myung-Ju,Han Ji-Youn,Kim Sang-We,Lee Ki Hyeong,Cho Eun Kyung,Haddish-Berhane Nahor,Mehta Jaydeep,Oh Se-Woong

Publisher

Elsevier BV

Reference28 articles.

1. Incidence, diagnosis, and management of QT prolongation induced by cancer therapies: a systematic review;Porta-Sánchez;J Am Heart Assoc,2017

2. Cardiotoxicity induced by tyrosine kinase inhibitors;Orphanos;Acta Oncol,2009

3. A comprehensive review of clinical cardiotoxicity incidence of FDA-approved small-molecule kinase inhibitors;Jin;Front Pharmacol,2020

4. Cardiovascular toxicity of tyrosine kinase inhibitors used in chronic myeloid leukemia: an analysis of the FDA Adverse Event Reporting System database (FAERS);Cirmi;Cancers (Basel),2020

5. Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors;Kloth;Br J Cancer,2015

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201;Lung Cancer;2024-04

2. Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset;Cancer Research and Treatment;2024-01-15

3. Real-world clinical evidence of lazertinib use in acquired EGFR T790M mutated non-small cell lung cancer;Translational Lung Cancer Research;2023-09

4. Cardiovascular toxicity of tyrosine kinase inhibitors during cancer treatment: Potential involvement of TRPM7;Frontiers in Cardiovascular Medicine;2023-02-03

5. Successful treatment of a patient with advanced lung adenocarcinoma (EGFR-T790M and C797S cis) with lazertinib: A case report and literature review;Frontiers in Oncology;2023-01-09